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Abstract  
Streptococcus pneumoniae (pneumococcus), a leading cause of morbidity and mortality 
worldwide, commonly colonizes the oronasopharynx asymptomatically but can on occasion 
progress beyond this site and cause disease. Pneumococcal colonization is a necessary precursor 
to disease and is dependent upon the ability of pneumococci to acquire and utilize carbohydrates. 
There are two main types of carbohydrate transporters encoded in the pneumococcal genome: the 
Phosphotranferase Systems (PTS) and the ATP-Binding Cassette (ABC) transporters. There are 
two proposed sucrose transporters encoded within the pneumococcus genome, a PTS, ScrT, and 
an ABC transporter, SusT1T2X. As ABC transporters are less energetically favorable than the 
PTS and are predicted to be subjected to catabolite repression, we hypothesize the main substrate 
of the SusT1T2X is not sucrose. The presence of a gene encoding sucrose hydrolase in the same 
genomic locus as susT1T2X led us to believe the main substrate of this transporter is sucrose-
containing. Inulin is a fructooligosaccharide (FOS) consisting of a long chain of fructose 
molecules with a terminal sucrose. Inulin is fermented by approximately 60% of pneumococcal 
strains yet the mechanism of utilization remained unknown. We have shown both inulin and 
shorter chains of FOS can support growth of the pneumococcal strain TIGR4 as a sole carbon 
source. An unmarked, nonpolar deletion of susT1T2X was created. This strain, TIGR4 
ΔsusT1T2X, was unable to utilize FOS longer than a glucose linked to three fructose. A 
genetically reconstituted strain was able to restore growth on these FOS indicating the sus locus 
is required for import of FOS. Furthermore, it has previously been reported that pneumococcal 
strains encode one of two distinct ABC transporters at the sus locus. Data suggest that while both 
transporters encoded at the sus locus allow for the import of short chain FOS, only one of the 
transporters allow for the import of long chain FOS, or inulin. 
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Introduction 
Streptococcus pneumoniae is a Gram positive, human pathogen that commonly colonizes the 
nasopharynx and is a major cause of disease worldwide. These diseases include pneumonia, 
otitis media, sinusitis, bacteremia, meningitis, and endocarditis. Current vaccines target the 
capsular polysaccharide of S. pneumoniae and because of this, they provide stereotype specific 
protection. S. pneumoniae is a very diverse species with over 90 different stereotypes making it 
difficult to provide protection against all strains (20).  In addition, treatment of disease is 
becoming increasingly challenging due to rising numbers of antibiotic resistant S. pneumoniae 
isolates (31).  Therefore, there is an interest in developing more effective vaccines and 
therapeutics.   
 
Pneumococcal colonization is often asymptomatic, but colonization is a necessary precursor to 
pneumococcal disease. S. pneumoniae requires carbohydrates for growth and therefore 
colonization, yet relatively little is known about how the bacteria acquire and utilize 
carbohydrates.  Free carbohydrates are relatively scarce in the nasopharynx, but the 
pneumococcus has developed ways of utilizing complex carbohydrates. It is known that 
pneumococci can cleave complex glycans that are found on the surface of human cells and as 
these carbohydrates have been shown to support pneumococcal growth in vitro, it is likely they 
do so in vivo as well (17, 23). It is also possible carbohydrates in the capsule of other bacteria are 
used as a carbon source in vivo as it has been shown that carbohydrates isolated from the capsule 
of bacteria can support pneumococcal growth in vitro (24).   
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Two main types of carbohydrate transporters have been identified in the S. pneumoniae genome: 
the Phosphotranferase Systems (PTS) and ATP-Binding-Cassette (ABC) transporters. The strain 
TIGR4 is predicted to encode 17 complete PTS and six ABC CUT1 transporters (35).  ABC 
CUT1 transporters are made up of a membrane bound substrate binding protein, membrane 
spanning permeases that form a channel through which the substrate enters the cell and two 
intracellular ATPases that bind to the permeases and hydrolyze ATP to energize transport. PTS 
transporters require less energy than the ABC transporters so the substrates of these transporters 
are predicted to be preferred carbohydrates.  Because of this, the ABC carbohydrate transporters 
in S. pneumoniae are predicted to be subjected to catabolite repression under favorable growth 
conditions. 
 
There are two predicted sucrose transporters encoded by pneumococci, a PTS, encoded by scrT 
and an ABC encoded by susT1T2X (Fig. 1) (15).  
 
 
 
 
 
 
 
Figure 1. Schematic of the two putative sucrose utilization operons encoded by the S. pneumoniae strainTIGR4. 
Open reading frames predicted within the TIGR4 sequence are represented by block arrows. 
 
susT1 and susT2 are predicted to encode the two permeases and susX is predicted to encode the 
substrate binding protein. Directly downstream of these genes is a gene encoding a predicted 
1 kb 
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sucrose hydrolase, SusH. Also in the same genomic locus is a predicted LacI family regulator, 
SusR. Interestingly, lacking in the genomic region is a gene(s) encoding an ATPase(s), an 
essential components of the transporter. All six ABC CUT1 transporters encoded by TIGR4 lack 
a gene(s) encoding an ATPase(s) in their genomic loci and the gene msmK is predicted to encode 
for the ATPase that energizes all six transporters (21). Because ABC transporters are believed to 
be repressed under favorable growth conditions, or when carbohydrates are being brought into 
the cell through the PTS, it seems unlikely sucrose is the primary substrate of both a PTS and an 
ABC transporter.  If there were both a sucrose PTS and ABC transporter, the ABC would be 
predicted to be subjected to catabolite repression when its substrate is present.  
 
ScrT and SusT1T2X were initially identified as sucrose transporters based on the presence of 
genes in their loci encoding glycosyl hydrolase 32 family proteins that contain a signature β-
fructosidase motif (NDPNG) and can contribute to growth on sucrose (11, 12, 15). It was shown 
that in the absence of either hydrolase, the other could compensate (15). It was subsequently 
shown that growth of a strain lacking scrT was reduced but not eliminated on sucrose. Growth of 
a strain lacking the substrate binding protein susX was not reduced on sucrose but a strain 
lacking both scrT and susX showed further reduction over the single mutant (4). This indicates 
that ScrT is the main sucrose transporter and that while SusT1T2X may contribute to sucrose 
transport in vitro, the main substrate of this transporter is not sucrose. This is further supported 
by the finding that sucrose induces expression of the scr locus but not the sus locus (15). In 
addition, it has previously been reported that sus locus contributes to in vivo fitness in the lung 
and not the nasopharynx suggesting the two transporters import different carbohydrates (15). 
Studies in our lab, using the strain TIGR4, we have shown the same phenotype as previously 
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demonstrated for the single mutants, but we have not seen consistent further reduction of growth 
on sucrose of TIGR4 Δscrt ΔsusT1T2X over TIGR4 Δscrt (TIGR4 Smr maximal OD600 nm ≥ 
0.69, TIGR4 Δscrt maximal OD600nm ≤ 0.44, TIGR4 ∆scrT ∆susT1T2X, maximal OD600nm ≥ 0.52) 
(Fig 2).  
 
 
 
 
 
 
 
 
Figure 2. scrT contributes to growth on sucrose. TIGR4 Sm
r, TIGR4 ΔsusT1T2X, TIGR4 ΔscrT and TIGR4 ΔscrT 
ΔsusT1T2X were grown for 60 h on chemically defined medium (CDM) supplemented with 12 mM sucrose as the 
sole carbon source.  Growth was measured by the optical density at 600 nm. A CDM no sugar control has been 
subtracted from each data set. This experiment was performed at least three independent times in triplicate and the 
OD600 values represent one experiment. 
 
While we propose the main substrate of SusT1T2X is not sucrose, the presence of the gene 
encoding a sucrose hydrolase within the predicted operon leads us to believe the main substrate 
of this transporter has a similar structure to sucrose.   
 
Inulin is a fructooligosaccharide (FOS) and naturally occurring fiber that acts a prebiotic.  It is a 
chain of fructose molecules joined by β(2-1) glycosidic bonds with a terminal α(1-2) glucose 
molecule. The terminal α(1-2) linked glucose and fructose is a sucrose molecule. It has been 
reported that about 60% of pneumococcal strains can ferment inulin (19, 27). The ability of S. 
pneumoniae to ferment inulin was first discovered in 1905 and has been used as a diagnostic tool 
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to distinguish between pneumococci and other airway pathogens (13). Some other bacterial 
species are able to ferment inulin and shorter FOS. These include Bifidobacteria and Lactobacilli 
(8, 10). FOS transporters in other bacteria include PTS, ABC and major facilitator superfamily 
proteins (2, 9, 32). To date, the mechanism of growth of pneumococci on inulin, including the 
transporter, is unknown. We hypothesize that the proposed ABC sucrose transporter, SusT1T2X, 
is responsible for the transport of inulin and related FOS.  
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Methods 
Bacterial Preparation and Growth Wild-type and genetically altered strains of S. pneumoniae 
and the recent clinical isolates used in this study are described in Table 1.  Broth cultures were 
grown at 37°C in Todd-Hewitt broth (Becton, Dickenson, and Co., Sparks, MD) supplemented 
with 0.2% w/v yeast extract (Becton, Dickenson, and Co.) (THY).  C media with 5% yeast 
extract (C+Y) pH 8 was used for transformations.  S. pneumoniae was also grown at 37°C and 5 
% CO2 overnight on tryptic soy (TS) (Becton, Dickenson, and Co.) plates with 1.5% agar that 
were spread with 5000 U catalase (Worthington Biochemical Corporation, Lakewood, NJ) prior 
to plating bacteria and TS plates supplemented with 5% sheep blood (Becton, Dickinson, and 
Co.).  Where appropriate, strains were selected for on TS plates that contained either 
streptomycin (200 µg/mL) or kanamycin (500 µg/mL) as appropriate. Unless otherwise stated, 
all carbohydrate solutions were sterilized using 0.22 µM Stericup (Millipore) filters. Unless 
otherwise indicated, all chemicals, substrates, and enzymes were purchased from Sigma 
Chemicals (St. Louis, MO). 
 
Inulin Preparation using 1905 Protocol Inulin media was prepared as described by Hiss (13). 
Briefly, 33 mL of fetal bovine serum was added to 67 mL of water in a glass bottle. One gram of 
inulin was added and the mixture was stirred until the inulin was dissolved. The mixture was 
then placed in a beaker of water heated to 100ºC for 10 minutes. This heating was repeated on 
the following two days.   
 
Genomic DNA Preparation All genomic DNA was prepared as previously described (36).  
Briefly, 10 mL of Optical Density at 600 nm (OD600) = 0.8 culture was centrifuged and re-
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suspended in 500 µL 50 mM ethylenediaminetetraacetic acid (EDTA)/ 10mM 
tris(hydroxymethyl)aminomethane (TRIS) (pH 8.0).  Bacteria were incubated at 37°C with 20 
µL 10 mg/mL lysozyme for 30 minutes (min) and subsequently with 30 µL 10 mg/mL proteinase 
K for an additional 30 min.  40 µL of 20 % v/v N-lauroyl sarcosine was added and mixed by 
inversion.  After 10 min bacteria were subjected to two rounds of extraction with an equal 
volume of phenol/chloroform/isoamyl alcohol (Fisher Scientific, Pittsburgh, PA) and a final 
extraction with an equal volume of chloroform.  DNA was isolated from the aqueous phase and 
precipitated with 100 % cold ethanol. The pellet was washed with 70 % v/v ethanol, vacuum 
dried, and re-suspended in 50 µL dH2O. 
 
Polymerase Chain Reaction All reactions were carried out in 0.2 mL flat cap PCR tubes.  
Master-mixes containing all reagents except the DNA template were pre-mixed and aliquoted 
into PCR tubes; DNA template was added individually to each reaction.  H2O rather than DNA 
template served as a negative control.  When possible, positive controls were included.   
Reactions using the high-fidelity polymerase, Phusion (New England Biolabs).  A high 
fidelity polymerase was used to create of the desired construct for transformation into S. 
pneumoniae.  To identify optimal amounts of DNA, neat, 1:5 and 1:10 dilutions of DNA were 
included until one was identified as most suitable.  Primers were used at 0.4 µg/µL per 
manufacturer’s instructions. 
Reagent         Amount (µL) 
5x Phusion PCR Buffer         5 
50x dNTP (10 mM each)         1 
Primer 1 (1 µg/µL)         0.2 
Primer 2 (1 µg/µL)         0.2 
Phusion polymerase         1 
Chromosomal DNA template          0.3 
De-ionized H2O        To 50 
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Thermocycling Parameters in the BioRad MyCycler™ Thermal Cycler 
 
95°C 
 
Denature 
 
30 s 
 
95°C Denature 10 s 
≥60°C Annealing 30 s 
72°C Elongation 30 s /kb 
 
72°C Polishing 10 min 
 
4°C 
  
   
The annealing temperature was determined for each reaction by estimating the temperature at 
which 50 % of the primer is dissociated (Tm) and using an annealing temperature 3°C less than 
that of the lowest primer if primer is twenty nucleotides or longer, if the primer is less than 
twenty nucleotides, the lower annealing temperature was used.  Estimation of primer Tm was 
performed by counting each cytosine or guanine as 4°C and each adenine or thymine as 2°C. 
Reactions using Choice™ Taq DNA Polymerase (Denville, Metuchen, NJ).  When 
amplifying products for sequencing or screening potential mutants with primers flanking the 
intended recombination site, standard Taq polymerase was used.  Standard 50 µL reaction:  
Reagents Amount (µL) 
10x PCR Buffer  5 
50x dNTP (10 mM each) 0.75 
MgCl2 (50mM) 0.5 
Primer 1 (1 µg/µL) 0.2 
Primer 2 (1 µg/µL) 0.2 
Taq polymerase (5U/µL) 0.2 
DNA template 0.3 
De-ionized H2O To 50 
 
 
 
 
 
1x 
 
30x 
 
 
1x 
HOLD 
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Thermocycling Parameters in the BioRad MyCycler™ Thermal Cycler 
95°C Denature 4min 
 
95°C Denature 1min 
55 ± 5°C Annealing 1min 
72°C Elongation 1min/kb 
 
72°C Polishing 1min/kb 
4°C   
    
   
 
Electrophoresis of DNA on a 1% agarose gel  Agarose gels were prepared by dissolving 
agarose in 1xTAE to 1% w/v.  Ethidium bromide (final concentration = 0.025 µg/mL) was added 
directly to the melted agarose.  To visualize chromosomal DNA or PCR products, 2 µL of DNA 
was mixed with 3 µL dH2O and 2 µL loading dye. Samples were electrophoresed horizontally at 
110 Volts in gels submerged in 1xTAE.  DNA was visualized by UV-transillumination. 
 
Sequence Analysis Before sequencing, PCR products were purified using the QIAquick PCR 
purification Kit (Qiagen). 50 ng/µl of purified PCR product was added to 4µl of the appropriate 
primer which was a concentration of 2µM. Sequencing reactions were done by Eurofins MWG 
Operon. DNA sequences of the genomic region flanking the gene(s) deleted of the mutant and 
parental sequences were compared using Lasergene SeqMan software (DNASTAR, Inc, 
Madison, WI).  If a discrepancy was found between sequencing reactions, the chromatographic 
output was analyzed to determine the correct base.  Sequence comparisons were performed using 
Lasergene MegAlign software. BLAST was used for protein sequence alignments and sequence 
identity.  
 
1x 
 
 
30x 
 
1x 
HOLD 
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Construction of Mutants All mutants were constructed using a Janus cassette selection system 
(34). This method requires two rounds of transformation. The first introduced a Janus cassette 
encoding kanamycin resistance and streptomycin sensitivity (rpsL
+
) into the genome of 
streptomycin-resistant (Sm
r
) S. pneumoniae strain in place of the region to be deleted. DNA 
fragments flanking the region to be deleted were amplified primers 1 and 2 (upstream region) 
and 4 and 5 (downstream region) and sequentially joined to the Janus cassette PCR product 
(primers J.F and J.R) using a variation of splicing by overlap extension (SOE) PCR (6), first 
described by Horton et al. (14).  Phusion was used to minimize PCR-generated errors. The Janus 
construct was transformed into S. pneumoniae and the transformants were selected for on TS 
plates containing kanamycin and confirmed by PCR using primers 7 and 8, which flank the 
mutant construct.  
 
The second round of transformation replaced the Janus cassette with an engineered segment of 
DNA consisting of the fragments flanking the deleted region. The fragments were generated 
using primers 1 and 3 (upstream fragment) and 5 and 6 (downstream fragment) and spliced 
together via SOE. The transformants were selected for on TS plates containing streptomycin. 
The unmarked mutants were confirmed with primers flanking the construct (primers 7 and 8) and 
sequencing. Mutants were grown on rich media to ensure no general growth defects were 
introduced during the mutant generation.  
 
The genetically reconstituted strains were generated by transforming the final mutants with the 
corresponding Janus construct and then subsequently with parental DNA. Genetic reconstitution 
was confirmed by primers flanking the construct (7 and 8). 
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RNA Preparation and Reverse Transcriptase RT-PCR RNA was isolated by an acid-phenol 
extraction, with modifications for S. pneumoniae (16). Bacteria were grown as described for 
above for growth assays, but a final volume of 10 ml was incubated in a 37°C water bath. When 
samples reached OD600 of 0.3 ± 0.005, they were combined with 10 ml acid phenol and 100 μl 
10% SDS and incubated at 90°C until the phases merged. Samples were then cooled on ice and 
centrifuged for 30 min at 3200 x g at 4°C.  Two additional extractions were performed first with 
equal volumes of 1:1 acid phenol:choloroform and then with chloroform. RNA was precipitated 
with 10 ml isopropanol and 2 ml of 3 M sodium acetate at -20°C overnight. RNA was 
concentrated and washed twice with 1 ml 70% ethanol and then vacuum dried. Resulting RNA 
was resuspended in 100 μl H2O, quantified, and adjusted to 100 μg 41 μl 
-1
 to allow for a final 
reaction volume of 50 μl for DNase treatment. Nucleic acid was incubated with 5 μl DNase I 
buffer, 3 μl DNase I (New England Biolabs) and 1 μl Super RNaseIN (Promega) at 37°C for 1 
hr. RNase-free reagents were used throughout.  cDNA was generated with SmartScribe reverse 
transcriptase as according to the manufacturer’s recommendations (New England Biolabs). 
Parallel samples were processed without addition of reverse transcriptase as a negative control. 
 
The Janus system of mutant generation is designed to generate unmarked nonpolar mutants; 
however, as the genes encoding SusT1T2X are predicted to be upstream of and in the same 
transcriptional unit as susH, nonpolarity of the mutants were confirmed by semi-quantitative 
reverse-transcriptase PCR using primers 9 and 10 designed within the gene susH. The 
housekeeping gene, aroE (primers A.1 and A.2), was used as a control for measuring the level 
of gene expression. All primers used can be found in Table 2. 
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Growth Assays Chemically defined media (CDM) was prepared essentially as previously 
described (18), without the addition of carbohydrate. The CDM buffer was made at 2.5 times 
concentration to allow addition of sufficient carbohydrate to support bacterial growth. The 
medium was supplemented with no sugar, 12mM glucose, 12mM sucrose, 5mg mL
-1 
inulin, 12 
mM kestose (Wako Chemicals), 12 mM  nystose (Wako Chemicals), 12 mM  
fructofranosylnystose (Wako Chemicals),or  2.7 mg ml
-1
 raftilose (Beneo-Orafti). S. pneumoniae 
strains were grown in THY to an optical density at 600 nm (OD600) = 0.3 ± 0.005, 1 mL aliquots 
were washed and resuspended in 65 µl of PBS and 65 µl of catalase (50,000 U mL
-1
). Twenty 
microliter aliquots of bacterial suspensions or PBS/catalase (no bacteria control) were transferred 
to 180 µl of CDM supplemented with the appropriate carbon source. Medium supplemented with 
glucose served as a positive control, indicating the bacterial were viable and that mutant strains 
showed no general growth defect relative to their parent strain. Medium with no added 
carbohydrate served as a negative control. Growth plates were incubated at 37°C for 60 h in a 
BIO-TEK Synergy HT plate reader and the OD600 was read every 20 min. All data were adjusted 
to a path-length of 1 cm. As no increase in optical density was observed for any bacterial strain 
on no-carbohydrate medium, at each time point the average of results from triplicate wells was 
subtracted from results from all other wells containing the same bacterial strain. Results from 
triplicate wells were then averaged. Growth experiments were performed three times in triplicate 
with the exception of the growth of clinical isolates on nystose and inulin. Clinical strains that 
showed no growth on these carbohydrates were tested at least one additional time. While each 
separate experiment showed the same trends, the growth profile varied so the graphs shown are 
representative curves.  
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Table 1: Strains used in this study.           
Strain Name   Serotype Characteristics/genotype
a
   Source or Reference 
TIGR4  
 
4 Clinical isolate 
  
(35) 
TIGR4 Sm
r
 
 
4 Lys→Thr in RpsL [rpsL(K56T)] conferring Smr (3) 
TIGR4 ΔmsmK 
 
4 ∆msmK rpsL(K56T) (Smr) 
 
This study 
TIGR4 ΔmsmK/msmK+ 
 
4 Lys→Thr in RpsL [rpsL(K56T)] conferring Smr This study 
TIGR4 ΔsusT1T2X 
 
4 ∆sus rpsL(K56T) (Smr) 
 
This study 
TIGR4 ΔsusT1T2X/susT1T2X+ 4 Lys→Thr in RpsL [rpsL(K56T)] conferring Smr This study 
TIGR4 ΔscrT 
 
4 ∆scrT rpsL(K56T) (Smr) 
 
This study 
TIGR4 ΔscrT/scrT+ 
 
4 Lys→Thr in RpsL [rpsL(K56T)] conferring Smr This study 
TIGR4 ΔscrTΔsusT1T2X 
 
4 ∆scrT ∆sus rpsL(K56T) (Smr) 
 
This study 
TIGR4 ΔscrTΔsusT1T2X/scrT+susT1T2X+ 4 Lys→Thr in RpsL [rpsL(K56T)] conferring Smr This study 
C06_4 
 
6A/B Clinical isolate 
  
This study 
C06_5 
 
15A Clinical isolate 
  
(24) 
C06_6 
 
19A Clinical isolate 
  
This study 
C06_8 
 
19A Clinical isolate 
  
This study 
C06_9 
 
19A Clinical isolate 
  
This study 
C06_10 
 
3 Clinical isolate 
  
(24) 
C06_12 
 
19A Clinical isolate 
  
This study 
C06_14 
 
19A Clinical isolate 
  
(24) 
C06_18 
 
22F Clinical isolate 
  
(6) 
C06_19 
 
6A/B Clinical isolate 
  
This study 
C06_20 
 
19A Clinical isolate 
  
This study 
C06_21 
 
19A Clinical isolate 
  
This study 
C06_23 
 
19A Clinical isolate 
  
This study 
C06_25 
 
3 Clinical isolate 
  
This study 
C06_31 
 
23F Clinical isolate 
  
(6) 
C06_34 
 
35F Clinical isolate 
  
This study 
C06_36 
 
19A Clinical isolate 
  
This study 
C06_39 
 
35F Clinical isolate 
  
(6) 
C06_40 
 
19A Clinical isolate 
  
This study 
C06_44 
 
19A Clinical isolate 
  
This study 
C06_45 
 
19A Clinical isolate 
  
This study 
C06_48 
 
19A Clinical isolate 
  
This study 
C06_50 
 
19A Clinical isolate 
  
This study 
C06_57 
 
6/AB Clinical isolate 
  
(6) 
C06_60 
 
19F Clinical isolate 
  
This study 
CI41 
 
19 Clinical isolate 
  
(28) 
Cr3 
 
4 Clinical isolate 
  
(28) 
CI7 
 
6B Clinical isolate 
  
(28) 
  
19 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Strains used in this study (continued).     
Strain Name  Serotype Characteristics/genotypea  Source or Reference 
Cr31 
 
11 Clinical isolate 
  
(28) 
Cl50 
 
23F Clinical isolate 
  
(28) 
Cl32 
 
15 Clinical isolate 
  
(28) 
Cl43 
 
19 Clinical isolate 
  
(28) 
Cl15 
 
9 Clinical isolate 
  
(28) 
Cl25 
 
12 Clinical isolate 
  
(28) 
a
 Sm
r
 indicates resistance to Streptomycin           
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 Group No. Primer Sequence (5' → 3')a Location (accession no.)b 
    
Janus J.F CCGTTTGATTTTTAATGGATAATG 7-30 (AY334019) 
 
J.R GGGCCCCTTTCCTTATGCTT 247511-247527 (AE005672) 
    
aroE A.1 GCCTTTGAGGCGACAGC 1299642-1299626 (AE005672) 
 
A.2 TGCAGTTCARAAACATWTTCTAA 1299164-1299186 (AE005672) 
    
susT1T2X U.1 GCAGGTGGAAGAGAAGCAG 1715812-1715830 (AE005672) 
 
U.2 CATTATCCATTAAAAATCAAACGGGGACAGTCATCAATAACAAGAG (1) 1715089-1715110 (AE005672) 
 
U.3 ATCATCCCACTCAGTATCAAGGACAGTCATCAATAACAAGAG (3) 1715089-1715110 (AE005672) 
 
U.4 AAGCATAAGGAAAGGGGCCCTTGATACTGAGTGGGATGAT
 
(2) 1711791-1711810 (AE005672) 
 
U.5 CCTAGTAGAACGATACAGCC 1711791-1711810 (AE005672) 
 
U.6 TTGATACTGAGTGGGATGAT 1711111-1711130 (AE005672) 
 
U.7 TGCGTCATAATAAAGTTGATGG 1715949-1715970 (AE005672) 
 
U.8 ATCTAACTCGAAGTAATCTGGG 1711011-1711032 (AE005672) 
 
U.9 CAGGCTCTGCCATTGTCA 1711373-1711390 (AE005672) 
 
U.10 TCCCTCACGCTGATAA 1710963-1710978 (AE005672) 
    
scrT C.1 CTCAACATGGTAATGAGTATGC 1627457-1627478 (AE005672) 
 
C.2 CATTATCCATTAAAAATCAAACGGTTCGCCCTTACGACTATTAT (1) 1627038-1627057 (AE005672) 
 
C.3 CACATTAGAGAGGATTGATTAGATTCGCCCTTACGACTATTAT (4) 1627038-1627057 (AE005672) 
 
C.4 AAGCATAAGGAAAGGGGCCCTCTAATCAATCCTCTCTAATGTG (2) 1625085-1625107 (AE005672) 
 
C.5 GACCAGCTGCATAACCTTCTA 1625085-1625107 (AE005672) 
 
C.6 TCTAATCAATCCTCTCTAATGTG 1624384-1624404 (AE005672) 
 
C.7 GGGTCGTTGAGAAGTCCTGTT 1627484-1627504 (AE005672) 
 
C.8 ACCTGTACGAGCTTCCAAACT 1624361-1624381 (AE005672) 
 
C.9 CAATTTCCAACAACAACTCC 1624845-1624864 (AE005672) 
 
C.10 CATAACCTTCTAGACATCCC 1624393-1624412 (AE005672) 
    
    
msmK M.1 TAGACAAAAGCAGAAACAAGGATC 1486427-1486450 (AE005672) 
 
M.2 CATTATCCATTAAAAATCAAACGGATGTCTTCTTTGCTGTATTTACGC (1)  1485931-1485954 (AE005672) 
 
M.3 CAAGTCAAATCCAAGCTCAACATGTCTTCTTTGCTGTATTTACGC (6) 1485931-1485954 (AE005672) 
 
M.4 GGAAAGGGGCCCAGGTGGTTGAGCTTGGATTTGACTTG (2) 1485183-1485203 (AE005672) 
 
M.5 GTTGAGCTTGGATTTGACTTG 1485183-1485203 (AE005672) 
 
M.6 TGACCTGCTTCTGACATTTGA 1484618-1484638 (AE005672) 
 
M.7 CTACACAAAAATAAGCTCCATAAT 1486508-1486531 (AE005672) 
 
M.8 TTCCCCTATTACACGCAACCT 1484490-1484510 (AE005672) 
    a 
Underlining indicates reverse complement sequence of primer J.F (1) J.R (2) U.6 (3) C.6 (4) H.6 (5) and M.6 (6). 
b
Locations are given as nucleotide positions in the indicated accession numbers. 
 
Table 2:  Primers used in this study. 
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Results  
susT1T2X is required for growth on FOS To determine if susT1T2X contributes to FOS 
utilization in the S. pneumoniae strain TIGR4 Sm
r
, an unmarked nonpolar deletion of the three 
transporter genes was generated. Growth on commercially available short chain FOS with the 
same linkages as inulin, glucose linked to two fructose (kestose or GF2), three fructose (nystose 
or GF3), or four fructose (fructofranosylnystose or GF4), oligofructose consisting of two to eight 
fructose, (raftilose) and inulin was tested. TIGR4 Sm
r
 was able to grow on all FOS tested, yet 
growth on GF2 (OD600nm  0.121) and oligofructose (OD600nm  0.28) was consistently less 
robust than growth on inulin (OD600nm = 0.25 to 0.55), GF3 and GF4 (OD600nm ≥ 0.60). TIGR4 
∆susT1T2X was unable to grow on GF3 and longer FOS (Fig 3). 
 
Figure 3.  susT1T2X is required for growth on GF3, GF4, inulin and oligofructose. TIGR4 Sm
r
 and TIGR4 
ΔsusT1T2X were grown for 60 h on chemically defined medium (CDM) supplemented with (A) 5 mg ml-1 inulin, 
(B) 12mM GF3, (C) 12 mM GF4, or (D) 2.7 mg ml
-1
 oligofructose as the sole carbon source.  Growth was measured 
by the optical density at 600 nm. A CDM no sugar control has been subtracted from each data set. Each experiment 
was performed at least three independent times in triplicate and the OD600 values represent one experiment. On the 
graphs, circles represent fructose molecules and triangles represent glucose molecules. 
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TIGR4 ∆susT1T2X grew comparably to TIGR4 Smr on glucose and a genetically reconstituted 
strain TIGR4 ∆susT1T2X/susT1T2X+ grew comparably to TIGR4 Smr on each carbohydrate 
tested indicating the phenotype seen with TIGR4 ∆susT1T2X is due only to the absence of the 
transporter genes (data not shown). Growth of TIGR4 ∆susT1T2X was not reduced on GF2 
indicating GF2 transport is not sus dependent. Growth on GF2 is partly due to the PTS sucrose 
transporter, ScrT, as a growth of TIGR4 ∆scrT is reduced, but not eliminated, compared to the 
parental strain on GF2 (Fig. 4). A double susT1T2X/scrT mutant showed no further reduction 
over the scrT mutant indicating the residual growth seen with the scrT mutant is not due to 
susT1T2X.  
 
 
 
 
 
 
 
 
Figure 4.  Growth on GF2 involves multiple transporters. TIGR4 Sm
r, TIGR4 ΔsusT1T2X, TIGR4 ΔscrT and 
TIGR4 ΔscrT ΔsusT1T2X were grown for 60 h on chemically defined medium (CDM) supplemented with 12 mM 
GF2 as the sole carbon source.  Growth was measured by the optical density at 600 nm. A CDM no sugar control 
has been subtracted from each data set. This experiment was performed at least three independent times in triplicate 
and the OD600 values represent one experiment. 
 
msmK is required for growth on FOS SusT1T2X is one of six CUT1 transporters encoded in 
the TIGR4 genome (35). All six of the transporters lack a gene encoding an ATPase in their 
genomic region, an essential component of the transporters (35). The gene msmK is predicted to 
encode for the ATPase that energizes all six carbohydrate ABC transporters (21). The substrates 
of three of the six transporters have been previously identified and MsmK has been shown to be 
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essential for growth on those three carbohydrates (1, 21, 22, 30). Growth of TIGR4 ∆msmK on 
GF3 was completely eliminated (maximal OD600nm  0.014) (Fig. 5) while TIGR4 ∆msmK grew 
normally on glucose and TIGR4 ∆msmK/∆msmK+ grew comparably to TIGR4 Smr on GF3 
(maximal OD600nm ≥ 0.52). These data indicate SusT1T2X is also energized by MsmK.  
 
 
 
 
 
 
 
 
 
Figure 5. msmK is required for growth on GF3. Growth of S. pneumoniae strain TIGR4 and TIGR4 ΔmsmK on 
chemically defined media (CDM) supplemented with 12 mM GF3 as the sole carbon source. A CDM no sugar 
control has been subtracted from each data set. The growth assay was performed three independent times in 
triplicate and the OD600 values represent one experiment. 
 
Media preparation affects pneumococcal growth on inulin It has been reported that there is 
strain-to-strain variation in the ability of pneumococci to utilize inulin for growth and while 
TIGR4 Sm
r 
was able to grow on inulin, another common lab strain 1121 Sm
r
 was unable to grow 
on inulin each time tested. The ability to ferment inulin was used as a diagnostic test for 
pneumococci yet not every strain can utilize inulin for growth. In 1905, to sterilize the inulin 
media, the media was heated at 100°C for ten minutes for three consecutive days (13). We 
proposed during this heating process some of the long fructose chains were broken down and it 
was these shorter fragments that the bacteria were using for growth. This hypothesis is supported 
by the fact that TIGR4 Sm
r
 and 1121 Sm
r
 were both able to grow on inulin media that had been 
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autoclaved (20 min, 120ºC, 17 PSI), not filter sterilized as was done with the rest of the 
carbohydrates (1121 Sm
r
 maximal OD600nm ≥ 0.20, TIGR4 Sm
r
 OD600nm ≥ 0.44) (Fig. 6).  
 
 
Figure 6. TIGR4 Sm
r
 and 1121 Sm
r
 can grow on autoclaved inulin. Growth of S. pneumoniae strain TIGR4 and 
1121 on chemically defined media (CDM) supplemented with 5 mg ml
-1
 autoclaved inulin as the sole carbon source. 
A CDM no sugar control has been subtracted from each data set. The growth assay was performed three independent 
times in triplicate and the OD600 values represent one experiment. 
 
Growth of TIGR4 ∆susT1T2X was completely eliminated on the autoclaved inulin indicating the 
growth seen was not due to free fructose, glucose or sucrose in the media (Fig. 7).  
 
 
 
 
 
 
 
 
 
Figure 7. susT1T2X is required for growth on autoclaved inulin. Growth of S. pneumoniae strain TIGR4 and TIGR4 
ΔsusT1T2X on chemically defined media (CDM) supplemented with 5 mg ml-1 autoclaved inulin as the sole carbon 
source. A CDM no sugar control has been subtracted from each data set. The growth assay was performed three 
independent times in triplicate and the OD600 values represent one experiment. 
 
TIGR4 ∆susT1T2X/susT1T2X+ grew comparably to TIGR4 Smr on the autoclaved inulin (data 
not shown). 
 TIGR4 Sm
r 
 TIGR4 ΔsusT1T2X 
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As the autoclaving process
 
most likely partially degraded the long fructose chains, this supports 
the hypothesis that short chain FOS support pneumococcal growth. The growth profile of 1121 
Sm
r
 indicates that while long-chain FOS (inulin) cannot support 1121 growth, short-chain FOS 
can.  We tried multiple times to recreate the inulin media used in 1905. TIGR4 Sm
r
 and 1121 
Sm
r
 were able to grow significantly on the 1905 prepared inulin yet so was TIGR4 ∆susT1T2X 
indicating the heating process caused too much degradation of the fructose chains (data not 
shown). 
 
Differences in the ability of pneumococcal strains to utilize inulin correlates with the 
transporter encoded at this genomic locus It has been reported the sus locus is not a core part 
of the pneumococcal genome (15, 29). While the predicted sucrose hydrolase, SusH, and the 
predicted LacI family repressor, SusR, are encoded by all sequenced strains, in some strains an 
alternate carbohydrate ABC transporter is encoded at the sus locus (Fig 8).  
 
 
 
 
 
 
Figure 8. Schematic of putative FOS ABC transporters in S. pneumoniae strains TIGR4 and R6. 1121 is not 
sequenced so R6 is used as a representative. The substrate binding proteins are in black and the membrane 
spanning permeases are gray. A lacI family repressor susR and a sucrose hydrolase susH are conserved across 
pneumococcal strains. Also conserved is the first gene in each proposed operon, which is predicted to be a 
transcriptional activator. 
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The two transporters share little sequence similarity in their predicated amino acid sequences. 
The substrate binding proteins essentially share no sequence similarity, while the two permease 
components share 27% and 30% amino acid identity over the full length of the predicted amino 
acid sequence. The sus locus is present in 104 of the 123 pneumococcal genomes available and 
the alternative carbohydrate ABC transporter is present in the remaining 19. 
 
While we currently do not have the sequence of 1121 Sm
r
, through PCR we were able to 
determine the alternate transporter is encoded at the sus locus. As TIGR4 and 1121 encode 
different transporters at the sus locus and we showed these strains differ in their ability to utilize 
long chain FOS, we investigated if the different transporters were responsible for the different 
phenotypes. Thirty-four recent clinical isolates representing 13 serotypes were PCR screened to 
determine which transporter was encoded at the sus locus. This was done using a common 
primer designed in the gene encoding the sucrose hydrolase and one of two unique primers 
designed in the gene encoding the substrate binding protein of sus and a gene encoding one of 
the permease proteins of the alternate transporter (sus-like). These 34 strains were also tested for 
growth on short chain (GF3) and long chain (inulin) FOS (Table 3). Thirty-two of the 34 strains 
were able to grow on GF3 (maximal OD600nm ranging from 0.34 to 0.97) and 27 of the 34 strains 
were able to grow on inulin (no growth was defined as OD600nm ≤ 0.02). All of the clinical 
isolates that were able to grow on inulin encode the same carbohydrate ABC transporter at the 
sus locus as TIGR4. Of the seven strains that did not grow on inulin, six of them encode the 
alternate transporter. One of the two strains that did not grow on GF3 encodes the alternate 
transporter and grew poorly on glucose compared to other strains indicating this strain may not 
grow well under laboratory conditions. One strain that did not grow on inulin encodes the same 
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transporter as TIGR4 yet is one of the strains that did not grow on GF3 indicating a protein(s) 
required for FOS utilization may not be functional. Currently, we do not have sequences of either 
strain that did not grow on GF3, so it is possible there is a mutation in a gene(s) required for FOS 
utilization. These data indicate both transporters encoded at the sus locus allow for import of 
short chain FOS but only the sus transporter allows for import of long chain FOS. 
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Strain 
Growth
a
   
Allele  
GF3 inulin   
     C06_4 + +   sus 
C06_5 + - 
 
sus-like 
C06_6 + + 
 
sus 
C06_8 + + 
 
sus 
C06_9 - -   sus-like 
C06_10 + + 
 
sus 
C06_12 + + 
 
sus 
C06_14 + + 
 
sus 
C06_18 + + 
 
sus 
C06_19 + - 
 
sus-like 
C06_20 + + 
 
sus 
C06_21 + - 
 
sus-like 
C06_23 + + 
 
sus 
C06_25 + + 
 
sus 
C06_31 + - 
 
sus-like 
C06_34 + + 
 
sus 
C06_36 + + 
 
sus 
C06_39 + + 
 
sus 
C06_40 + + 
 
sus 
C06_44 + + 
 
sus 
C06_45 + + 
 
sus 
C06_48 + + 
 
sus 
C06_50 + + 
 
sus 
C06_57 + - 
 
sus-like 
C06_60 + + 
 
sus 
Cl41 + + 
 
sus 
Cr3 + + 
 
sus 
Cl7 + + 
 
sus 
Cr31 + + 
 
sus 
Cl50 + + 
 
sus 
Cl32 + + 
 
sus 
Cl43 + - 
 
sus-like 
Cl15 + + 
 
sus 
Cl25 + +   sus 
aNo growth is defined as not reaching an OD600 higher than 0.02 
Table 3. Growth of Clinical Isolates on GF3 and inulin 
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Discussion 
It has been previously demonstrated that SusT1T2X contributes to sucrose transport in vitro (15). 
However, we showed that a mutant in susT1T2X does not affect growth on sucrose and a double 
mutant in the sucrose PTS, scrT, and susT1T2X is no further reduced in growth over the single 
PTS mutant. This evidence suggests ScrT is the major sucrose transporter and that the main 
substrate of SusT1T2X is another carbohydrate. 
 
Inulin is known to be fermented by about 60% of pneumococcal strains yet no transporter had 
been identified  (19, 27). The findings in the study show that S. pneumoniae can utilize multiple 
lengths of FOS for growth. Growth of a TIGR4 susT1T2X mutant was completely eliminated on 
all FOS tested longer than GF2, including inulin, supporting the hypothesis that SusT1T2X acts 
as a FOS and not a sucrose transporter. 
 
The TIGR4 susT1T2X mutant showed no reduction in growth on GF2 compared to the parent 
strain. The data show GF2 is transported by multiple transporters as an scrT mutant was reduced 
but not eliminated in growth compared to the parent strain. A double scrT/susT1T2X mutant 
showed no additional reduction compared to the single scrT mutant indicating the residual 
growth seen with the scrT mutant is not due to SusT1T2X. Currently we do not know what other 
transporter(s) are contributing to growth on GF2. Raffinose is a sucrose containing carbohydrate 
and is known to be fermented by pneumococci so it is possible the raffinose transporter, encoded 
by rafEFG (SP1895-7), is contributing to growth on GF2 (30). 
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We have demonstrated the ATPase MsmK is required for growth on GF3. SusT1T2X is one of 
six CUT1 family transporters encoded by TIGR4, all of which lack a gene encoding an ATPase 
in their genomic region. SusT1T2X is the fourth CUT1 family transporter to be shown to require 
MsmK to be functional providing more evidence to support the hypothesis that MsmK energizes 
all six CUT1 family transporters. It was recently reported MsmK was not required for growth on 
sucrose and this was used as evidence to suggest MsmK does not energize SusT1T2X (4). As we 
believe the main sucrose transporter is part of the PTS, we would predict MsmK would play no 
role in sucrose transport.  
 
While it is known that some bacteria degrade FOS outside the cell, no extracellular enzyme has 
been identified in S. pneumoniae that would be involved in the breakdown of FOS before 
transport (35). It is currently unknown what lengths of inulin pneumococci are actually 
importing. By performing mass spectrometry on media before and after bacterial incubation, we 
may be able to determine exactly what chain lengths of inulin are being utilized by S. 
pneumoniae. Also, structuring the substrate binding proteins of the sus transporter and the 
alternate transporter would provide information about the binding pocket and may help 
determine which lengths of FOS are binding to each protein. This may help determine whether 
the substrate binding protein or permeases are responsible for the differences in specificity 
between the two transporters at the sus locus.  
 
While inulin was reported to be fermented by pneumococci in 1905, it has also been reported 
that not every strain can ferment inulin (4, 13, 19, 27). It has also been reported the sus locus is 
not a core part of the pneumococcal genome; in some strains there is an alternate carbohydrate 
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ABC transporter encoded at that locus (15, 29). Both transporters appear to be FOS transporters 
yet we have had difficulty in making a mutant of the alternate transporter. An msmK mutant in a 
strain encoding the alternate ABC transporter is unable to grow on GF3, indicating transport is 
through an ABC transporter and the best candidate is the one encoded at the sus locus. It is 
interesting that both transporters are being maintained in the population. While it is possible the 
two transporters are important during different phases of pathogenesis, so far we have seen no 
evidence of a correlation between site of isolation and the transporter encoded. As both 
transporters appear to allow for the import of short chain FOS, it seems more likely that the 
biologically relevant substrate is transported equally well by both transporters.  
 
It has previously been reported that sus locus contributes to in vivo fitness in the lung and not the 
nasopharynx. It is unlikely FOS are present in the lung but it is possible the transporter has other 
substrates that are. Inulin and other FOS are not synthesized by humans and are typically 
considered dietary carbohydrates. There is evidence that pneumococci can be found in the mouth 
yet the number and frequency of this is unknown. There are a number of dietary carbohydrates 
known to be fermented by pneumococci indicating the bacteria may see them during some stage 
of pathogenesis (4, 25, 26, 33). Another possible source of FOS in vivo is from fructans made by 
other bacteria. There is evidence that some bacteria species, including S. mutans, express 
extracellular polysaccharide consisting of fructans with the same structure as oligofructose (5, 7). 
This suggests that bacteria in the same niche as the pneumococcus may produce fructans that can 
be utilized by the pneumococcus for growth. Previous studies have suggested that pneumococci 
can utilize capsular carbohydrates produced by other bacteria for growth; for example the 
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Streptococcus pyogenes hyaluronic acid capsule can be used by pneumococci a sole carbon 
source (24). 
 
Sequence homology searches revealed that the genes encoding the alternative transporter are 
closely related to a predicted ABC transporter encoded by Streptococcus mitis. Comparison of 
the sequence of D39 which encodes the alternative ABC transporter and S. mitis strain NCTC 
12261 revealed 98.5% identity between the nucleotide sequences and 99% identity between the 
predicted amino acid sequences of the substrate binding proteins. Furthermore, each permease 
component encoded by D39 shares greater than 98.8% identity at both the nucleotide and amino 
acid levels with the putative permeases encoded by NCTC 12261. These data suggest that the 
alternative locus may have been introduced into pneumococci through homologous 
recombination with S. mitis. 
 
In summary, the data presented here demonstrate the mechanism by which pneumococci utilize 
FOS and determines the likely reason for the previously identified variation in the ability of 
pneumococci to utilize inulin.  
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